megapharma ltd
megapharma ltd Company Information
Company Number
08199172
Next Accounts
Jun 2025
Shareholders
capital holder
Group Structure
View All
Industry
Research and experimental development on biotechnology
+2Registered Address
a11 2 alexandra gate, cardiff, CF24 2SA
Website
oetliker.infomegapharma ltd Estimated Valuation
Pomanda estimates the enterprise value of MEGAPHARMA LTD at £91.3k based on a Turnover of £109.2k and 0.84x industry multiple (adjusted for size and gross margin).
megapharma ltd Estimated Valuation
Pomanda estimates the enterprise value of MEGAPHARMA LTD at £0 based on an EBITDA of £0 and a 3.78x industry multiple (adjusted for size and gross margin).
megapharma ltd Estimated Valuation
Pomanda estimates the enterprise value of MEGAPHARMA LTD at £194 based on Net Assets of £100 and 1.94x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Megapharma Ltd Overview
Megapharma Ltd is a live company located in cardiff, CF24 2SA with a Companies House number of 08199172. It operates in the manufacture of basic pharmaceutical products sector, SIC Code 21100. Founded in September 2012, it's largest shareholder is capital holder with a 100% stake. Megapharma Ltd is a established, micro sized company, Pomanda has estimated its turnover at £109.2k with healthy growth in recent years.
Upgrade for unlimited company reports & a free credit check
Megapharma Ltd Health Check
Pomanda's financial health check has awarded Megapharma Ltd a 0.5 rating. We use a traffic light system to show it exceeds the industry average on 0 measures and has 5 areas for improvement. Company Health Check FAQs
0 Strong
1 Regular
5 Weak
Size
annual sales of £109.2k, make it smaller than the average company (£13.4m)
- Megapharma Ltd
£13.4m - Industry AVG
Growth
3 year (CAGR) sales growth of 4%, show it is growing at a slower rate (7.4%)
- Megapharma Ltd
7.4% - Industry AVG
Production
with a gross margin of 20.9%, this company has a higher cost of product (43.2%)
- Megapharma Ltd
43.2% - Industry AVG
Profitability
There is insufficient data available for this Key Performance Indicator!
- Megapharma Ltd
- - Industry AVG
Employees
with 1 employees, this is below the industry average (61)
1 - Megapharma Ltd
61 - Industry AVG
Pay Structure
on an average salary of £62k, the company has an equivalent pay structure (£62k)
- Megapharma Ltd
£62k - Industry AVG
Efficiency
resulting in sales per employee of £109.2k, this is less efficient (£229.6k)
- Megapharma Ltd
£229.6k - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- Megapharma Ltd
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- Megapharma Ltd
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- Megapharma Ltd
- - Industry AVG
Cash Balance
There is insufficient data available for this Key Performance Indicator!
- - Megapharma Ltd
- - Industry AVG
Debt Level
There is insufficient data available for this Key Performance Indicator!
- - Megapharma Ltd
- - Industry AVG
MEGAPHARMA LTD financials
Megapharma Ltd's latest turnover from September 2023 is estimated at £109.2 thousand and the company has net assets of £100. According to their latest financial statements, Megapharma Ltd has 1 employee and maintains cash reserves of 0 as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 | Sep 2015 | Sep 2014 | Sep 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | |||||||||||
| Other Income Or Grants | |||||||||||
| Cost Of Sales | |||||||||||
| Gross Profit | |||||||||||
| Admin Expenses | |||||||||||
| Operating Profit | |||||||||||
| Interest Payable | |||||||||||
| Interest Receivable | |||||||||||
| Pre-Tax Profit | |||||||||||
| Tax | |||||||||||
| Profit After Tax | |||||||||||
| Dividends Paid | |||||||||||
| Retained Profit | |||||||||||
| Employee Costs | |||||||||||
| Number Of Employees | 1 | 1 | 1 | 1 | 1 | ||||||
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 | Sep 2015 | Sep 2014 | Sep 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments & Other | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock & work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Misc Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total assets | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| net assets | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 | 0 |
| total shareholders funds | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 | Sep 2015 | Sep 2014 | Sep 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||
| Operating Profit | |||||||||||
| Depreciation | 0 | 0 | 0 | 0 | 0 | ||||||
| Amortisation | 0 | 0 | 0 | 0 | 0 | ||||||
| Tax | |||||||||||
| Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creditors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash flow from operations | |||||||||||
| Investing Activities | |||||||||||
| capital expenditure | |||||||||||
| Change in Investments | 0 | 0 | 0 | 0 | 100 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from investments | |||||||||||
| Financing Activities | |||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | |||||||||||
| interest | |||||||||||
| cash flow from financing | |||||||||||
| cash and cash equivalents | |||||||||||
| cash | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
megapharma ltd Credit Report and Business Information
Megapharma Ltd Competitor Analysis
Perform a competitor analysis for megapharma ltd by selecting its closest rivals, whether from the MANUFACTURING sector, other micro companies, companies in CF24 area or any other competitors across 12 key performance metrics.
megapharma ltd Ownership
MEGAPHARMA LTD group structure
Megapharma Ltd has no subsidiary companies.
megapharma ltd directors
Megapharma Ltd currently has 2 directors. The longest serving directors include Mr Philipp Mengpah (Dec 2019) and Mr Philipp Mengpah (Aug 2023).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Philipp Mengpah | England | 37 years | Dec 2019 | - | Director |
| Mr Philipp Mengpah | England | 37 years | Aug 2023 | - | Director |
P&L
September 2023turnover
109.2k
+8%
operating profit
0
0%
gross margin
20.9%
-8.2%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
September 2023net assets
100
0%
total assets
100
0%
cash
0
0%
net assets
Total assets minus all liabilities
Similar Companies
megapharma ltd company details
company number
08199172
Type
Private limited with Share Capital
industry
21100 - Manufacture of basic pharmaceutical products
72110 - Research and experimental development on biotechnology
82990 - Other business support service activities n.e.c.
incorporation date
September 2012
age
13
incorporated
UK
ultimate parent company
accounts
Micro-Entity Accounts
last accounts submitted
September 2023
previous names
cardiff management & secretarial ltd. (December 2019)
accountant
-
auditor
-
address
a11 2 alexandra gate, cardiff, CF24 2SA
Bank
-
Legal Advisor
-
megapharma ltd Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to megapharma ltd.
megapharma ltd Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for MEGAPHARMA LTD. This can take several minutes, an email will notify you when this has completed.
megapharma ltd Companies House Filings - See Documents
| date | description | view/download |
|---|
